{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:23:34Z","timestamp":1770135814671,"version":"3.49.0"},"reference-count":102,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2007,12,7]],"date-time":"2007-12-07T00:00:00Z","timestamp":1196985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,1,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>OTHER ARTICLES PUBLISHED IN THIS TRANSLATIONAL MINI-REVIEW SERIES ON COMPLEMENT FACTOR H<\/jats:p><jats:p>Genetics and disease associations of human complement factor H. Clin Exp Immunol 2008; 151: doi:10.1111\/j.1365-2249.2007.03552.x<\/jats:p><jats:p>Structural and functional correlations for factor H. Clin Exp Immunol 2008; 151: doi:10.1111\/j.1365-2249.2007.03553.x<\/jats:p><jats:p>Renal diseases associated with complement factor H: novel insights from humans and animals. Clin Exp Immunol 2008; 151: doi:10.1111\/j.1365-2249.2007.03574.x<\/jats:p><jats:p>Genetic and acquired abnormalities in complement factor H (CFH) have been associated with two different human renal diseases: haemolytic uraemic syndrome and membrano proliferative glomerulonephritis. The new genetic and pathogenetic findings in these diseases and their clinical implications for the management and cure of patients are reviewed in this paper.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2007.03558.x","type":"journal-article","created":{"date-parts":[[2010,7,27]],"date-time":"2010-07-27T09:55:19Z","timestamp":1280224519000},"page":"199-209","source":"Crossref","is-referenced-by-count":31,"title":["Translational Mini-Review Series on Complement Factor H: Therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis"],"prefix":"10.1093","volume":"151","author":[{"given":"M","family":"Noris","sequence":"first","affiliation":[{"name":"Clinical Research Center for Rare Diseases \u2018Aldo e Cele Dacc\u00f2\u2019, Mario Negri Institute for Pharmacological Research, Villa Camozzi\u2003\u2212\u2003Ranica (BG)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Remuzzi","sequence":"additional","affiliation":[{"name":"Clinical Research Center for Rare Diseases \u2018Aldo e Cele Dacc\u00f2\u2019, Mario Negri Institute for Pharmacological Research, Villa Camozzi\u2003\u2212\u2003Ranica (BG)"},{"name":"Division of Nephrology and Dialysis, Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2007,12,7]]},"reference":[{"key":"2022010406275294500_b1","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1681\/ASN.2004100861","article-title":"Hemolytic uremic syndrome","volume":"16","author":"Noris","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2022010406275294500_b2","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0140-6736(98)01267-7","article-title":"Escherichia coli O157:H7","volume":"352","author":"Mead","year":"1998","journal-title":"Lancet"},{"key":"2022010406275294500_b3","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1681\/ASN.V2111640","article-title":"Renal function at hospital admission as a prognostic factor in adult hemolytic uremic syndrome. The Italian Registry of Haemolytic Uremic Syndrome","volume":"2","author":"Schieppati","year":"1992","journal-title":"J Am Soc Nephrol"},{"key":"2022010406275294500_b4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00467-003-1385-9","article-title":"Clinico-pathological findings in diarrhoea-negative haemolytic uraemic syndrome","volume":"19","author":"Taylor","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"2022010406275294500_b5","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.ajkd.2004.02.010","article-title":"Non-enteropathic hemolytic uremic syndrome: causes and short-term course","volume":"43","author":"Constantinescu","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"2022010406275294500_b6","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/humu.20435","article-title":"The interactive factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and factor I mutations with structural models","volume":"28","author":"Saunders","year":"2007","journal-title":"Hum Mutat"},{"key":"2022010406275294500_b7","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1136\/jmg.40.9.676","article-title":"Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries","volume":"40","author":"Neumann","year":"2003","journal-title":"J Med Genet"},{"key":"2022010406275294500_b8","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"key":"2022010406275294500_b9","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.molmed.2004.03.006","article-title":"Mutations in CD46, a complement regulatory protein, predispose to atypical HUS","volume":"10","author":"Goodship","year":"2004","journal-title":"Trends Mol Med"},{"key":"2022010406275294500_b10","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/S0140-6736(03)14742-3","article-title":"Familial haemolytic uraemic syndrome and an MCP mutation","volume":"362","author":"Noris","year":"2003","journal-title":"Lancet"},{"key":"2022010406275294500_b11","doi-asserted-by":"crossref","first-page":"12966","DOI":"10.1073\/pnas.2135497100","article-title":"Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome","volume":"100","author":"Richards","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022010406275294500_b12","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1136\/jmg.2004.019083","article-title":"Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome","volume":"41","author":"Fremeaux-Bacchi","year":"2004","journal-title":"J Med Genet"},{"key":"2022010406275294500_b13","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1681\/ASN.2005010103","article-title":"Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome","volume":"16","author":"Kavanagh","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2022010406275294500_b14","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1073\/pnas.0603420103","article-title":"Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome","volume":"104","author":"Goicoechea de Jorge","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022010406275294500_b15","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.molimm.2005.11.008","article-title":"Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree","volume":"43","author":"Esparza-Gordillo","year":"2006","journal-title":"Mol Immunol"},{"key":"2022010406275294500_b16","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1093\/hmg\/ddg363","article-title":"Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease","volume":"12","author":"Caprioli","year":"2003","journal-title":"Hum Mol Genet"},{"key":"2022010406275294500_b17","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0002-9343(99)00286-7","article-title":"Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura\u2013hemolytic uremic syndrome","volume":"107","author":"Lara","year":"1999","journal-title":"Am J Med"},{"key":"2022010406275294500_b18","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura\u2013hemolytic uremic syndrome. Clinical experience in 108 patients","volume":"325","author":"Bell","year":"1991","journal-title":"N Engl J Med"},{"key":"2022010406275294500_b19","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1046\/j.1523-1755.2001.060003831.x","article-title":"Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura","volume":"60","author":"Ruggenenti","year":"2001","journal-title":"Kidney Int"},{"key":"2022010406275294500_b20","doi-asserted-by":"crossref","first-page":"453","DOI":"10.7326\/0003-4819-131-6-199909210-00011","article-title":"Therapeutic plasma exchange: an update from the Canadian Apheresis Group","volume":"131","author":"Clark","year":"1999","journal-title":"Ann Intern Med"},{"key":"2022010406275294500_b21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/ajh.2830340303","article-title":"Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura","volume":"34","author":"Byrnes","year":"1990","journal-title":"Am J Hematol"},{"key":"2022010406275294500_b22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"key":"2022010406275294500_b23","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1067\/mpd.2001.112649","article-title":"Familial hemolytic uremic syndrome associated with complement factor H deficiency","volume":"138","author":"Landau","year":"2001","journal-title":"J Pediatr"},{"key":"2022010406275294500_b24","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1007\/s00467-004-1526-9","article-title":"Challenges in the management of infantile factor H associated hemolytic uremic syndrome","volume":"19","author":"Filler","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"2022010406275294500_b25","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s00467-007-0438-x","article-title":"Complete factor H deficiency-associated atypical hemolytic uremic syndrome in a neonate","volume":"22","author":"Cho","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"2022010406275294500_b26","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s00467-003-1192-3","article-title":"Successful (?) therapy of hemolytic\u2013uremic syndrome with factor H abnormality","volume":"18","author":"Gerber","year":"2003","journal-title":"Pediatr Nephrol"},{"key":"2022010406275294500_b27","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1053\/j.ajkd.2004.10.018","article-title":"Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15","volume":"45","author":"Licht","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"2022010406275294500_b28","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/ndt\/17.4.684","article-title":"Successful treatment of factor H-related haemolytic uraemic syndrome","volume":"17","author":"Stratton","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"2022010406275294500_b29","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1053\/j.ajkd.2005.11.007","article-title":"Complement factor H-associated atypical hemolytic uremic syndrome in monozygotic twins: concordant presentation, discordant response to treatment","volume":"47","author":"Davin","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"2022010406275294500_b30","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ki.1996.40","article-title":"Bilateral nephrectomy stopped disease progression in plasma-resistant hemolytic uremic syndrome with neurological signs and coma","volume":"49","author":"Remuzzi","year":"1996","journal-title":"Kidney Int"},{"key":"2022010406275294500_b31","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/ndt\/12.7.1425","article-title":"Recurrence of haemolytic\u2013uraemic syndrome in renal transplants: a single-centre report","volume":"12","author":"Miller","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"2022010406275294500_b32","doi-asserted-by":"crossref","first-page":"E22","DOI":"10.1053\/ajkd.2002.36938","article-title":"Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor","volume":"40","author":"Donne","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2022010406275294500_b33","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2215\/CJN.00050505","article-title":"Outcome of renal transplantation in patients with non-Shiga toxin-associated haemolytic uremic syndrome: prognostic significance of genetic background","volume":"1","author":"Bresin","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022010406275294500_b34","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00467-004-1565-2","article-title":"Atypical relapse of hemolytic uremic syndrome after transplantation","volume":"19","author":"Olie","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"2022010406275294500_b35","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/j.1600-6143.2005.00783.x","article-title":"Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor H gene mutation","volume":"5","author":"Remuzzi","year":"2005","journal-title":"Am J Transplant"},{"key":"2022010406275294500_b36","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/S0140-6736(02)08560-4","article-title":"Combined kidney and liver transplantation for familial haemolytic uraemic syndrome","volume":"359","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"key":"2022010406275294500_b37","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1111\/j.1600-6143.2006.01375.x","article-title":"Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation","volume":"6","author":"Saland","year":"2006","journal-title":"Am J Transplant"},{"key":"2022010406275294500_b38","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1016\/j.molimm.2007.06.167","article-title":"Combined liver\u2013kidney transplantation is a possible treatment for patients with atypical hemolytic uremic syndrome associated with factor H mutations","volume":"44","author":"Koskinen","year":"2007","journal-title":"Mol Immunol"},{"key":"2022010406275294500_b39","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00467-006-0320-2","article-title":"A missense mutation in factor I (IF) predisposes to atypical haemolytic uraemic syndrome","volume":"22","author":"Geelen","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"2022010406275294500_b40","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1681\/ASN.2004050380","article-title":"Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome","volume":"16","author":"Dragon-Durey","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2022010406275294500_b41","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1182\/blood-2007-02-071472","article-title":"Anti-factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome","volume":"110","author":"Jozsi","year":"2007","journal-title":"Blood"},{"key":"2022010406275294500_b42","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1681\/ASN.2005010078","article-title":"Membranoproliferative glomerulonephritis type II (dense deposit disease): an update","volume":"16","author":"Appel","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2022010406275294500_b43","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199804233381707","article-title":"The nephrotic syndrome","volume":"338","author":"Orth","year":"1998","journal-title":"N Engl J Med"},{"key":"2022010406275294500_b44","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ki.1975.32","article-title":"Dense deposit disease: a variant of membranoproliferative glomerulonephritis","volume":"7","author":"Habib","year":"1975","journal-title":"Kidney Int"},{"key":"2022010406275294500_b45","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.molimm.2005.06.015","article-title":"Complement and diseases: defective alternative pathway control results in kidney and eye diseases","volume":"43","author":"Zipfel","year":"2006","journal-title":"Mol Immunol"},{"key":"2022010406275294500_b46","doi-asserted-by":"crossref","first-page":"25168","DOI":"10.1074\/jbc.272.40.25168","article-title":"Human factor H deficiency. Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism","volume":"272","author":"Ault","year":"1997","journal-title":"J Biol Chem"},{"key":"2022010406275294500_b47","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/01.ASN.0000115702.28859.A7","article-title":"Heterozygous and homozygous factor H deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases","volume":"15","author":"Dragon-Durey","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2022010406275294500_b48","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/ki.1986.278","article-title":"H deficiency in two brothers with atypical dense intramembranous deposit disease","volume":"30","author":"Levy","year":"1986","journal-title":"Kidney Int"},{"key":"2022010406275294500_b49","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/sj.ki.5000269","article-title":"Deletion of Lys224 in regulatory domain 4 of factor H reveals a novel pathomechanism for dense deposit disease (MPGN II)","volume":"70","author":"Licht","year":"2006","journal-title":"Kidney Int"},{"key":"2022010406275294500_b50","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1034\/j.1399-3038.2001.012003166.x","article-title":"Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up","volume":"12","author":"Schwertz","year":"2001","journal-title":"Pediatr Allergy Immunol"},{"key":"2022010406275294500_b51","first-page":"420","volume-title":"The complement system","author":"Kirschfink","year":"1998"},{"key":"2022010406275294500_b52","doi-asserted-by":"crossref","first-page":"755","DOI":"10.4049\/jimmunol.123.2.755","article-title":"Further evidence for the antibody nature of C3 nephritic factor (C3NeF)","volume":"123","author":"Daha","year":"1979","journal-title":"J Immunol"},{"key":"2022010406275294500_b53","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0022-1759(01)00295-2","article-title":"A C3 convertase assay for nephritic factor functional activity","volume":"251","author":"Jelezarova","year":"2001","journal-title":"J Immunol Methods"},{"key":"2022010406275294500_b54","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1084\/jem.177.6.1827","article-title":"Complement-mediated adipocyte lysis by nephritic factor sera","volume":"177","author":"Mathieson","year":"1993","journal-title":"J Exp Med"},{"key":"2022010406275294500_b55","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0272-6386(12)81018-3","article-title":"Patterns of complement activation in idiopathic membranoproliferative glomerulonephritis, types I, II, and III","volume":"16","author":"Varade","year":"1990","journal-title":"Am J Kidney Dis"},{"key":"2022010406275294500_b56","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1084\/jem.175.4.939","article-title":"Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis","volume":"175","author":"Meri","year":"1992","journal-title":"J Exp Med"},{"key":"2022010406275294500_b57","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/MNH.0b013e3280bdc0f4","article-title":"Dense deposit disease: new insights","volume":"16","author":"Walker","year":"2007","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2022010406275294500_b58","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.1016\/S0272-6386(03)00665-6","article-title":"Visual impairment caused by retinal abnormalities in mesangiocapillary (membranoproliferative) glomerulonephritis type II (\u2018dense deposit disease\u2019)","volume":"42","author":"Colville","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2022010406275294500_b59","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1126\/science.1110189","article-title":"Complement factor H polymorphism and age-related macular degeneration","volume":"308","author":"Edwards","year":"2005","journal-title":"Science"},{"key":"2022010406275294500_b60","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1126\/science.1109557","article-title":"Complement factor H polymorphism in age-related macular degeneration","volume":"308","author":"Klein","year":"2005","journal-title":"Science"},{"key":"2022010406275294500_b61","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1126\/science.1110359","article-title":"Complement factor H variant increases the risk of age-related macular degeneration","volume":"308","author":"Haines","year":"2005","journal-title":"Science"},{"key":"2022010406275294500_b62","doi-asserted-by":"crossref","first-page":"7227","DOI":"10.1073\/pnas.0501536102","article-title":"A common haplotype in the complement regulatory gene factor H (HF1\/CFH) predisposes individuals to age-related macular degeneration","volume":"102","author":"Hageman","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022010406275294500_b63","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/jmg.2005.038315","article-title":"Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease)","volume":"43","author":"Abrera-Abeleda","year":"2006","journal-title":"J Med Genet"},{"key":"2022010406275294500_b64","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/ki.1986.110","article-title":"Childhood membranoproliferative glomerulonephritis: an approach to management","volume":"29","author":"West","year":"1986","journal-title":"Kidney Int"},{"key":"2022010406275294500_b65","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF00866289","article-title":"Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone \u2212 a report of the International Study of Kidney Disease in Children","volume":"6","author":"Tarshish","year":"1992","journal-title":"Pediatr Nephrol"},{"key":"2022010406275294500_b66","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0272-6386(89)80143-X","article-title":"Reassessment of treatment results in membranoproliferative glomerulonephritis, with emphasis on life-table analysis","volume":"14","author":"Donadio","year":"1989","journal-title":"Am J Kidney Dis"},{"key":"2022010406275294500_b67","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1681\/ASN.2007030356","article-title":"New approaches to the treatment of dense deposits disease","volume":"18","author":"Smith","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2022010406275294500_b68","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0272-6386(88)80009-X","article-title":"Regression of membranoproliferative glomerulonephritis type II (dense deposit disease): observations in six children","volume":"12","author":"McEnery","year":"1988","journal-title":"Am J Kidney Dis"},{"key":"2022010406275294500_b69","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S0272-6386(99)70007-7","article-title":"Differences between membranoproliferative glomerulonephritis types I and III in long-term response to an alternate-day prednisone regimen","volume":"34","author":"Braun","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"2022010406275294500_b70","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s10157-004-0329-4","article-title":"Steroid resistance in prolonged type I membranoproliferative glomerulonephritis and accelerated disease remission after steroid withdrawal","volume":"9","author":"Kazama","year":"2005","journal-title":"Clin Exp Nephrol"},{"key":"2022010406275294500_b71","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1046\/j.1523-1755.1999.07006.x","article-title":"Management of membranoproliferative glomerulonephritis: evidence-based recommendations","volume":"70","author":"Levin","year":"1999","journal-title":"Kidney Int Suppl"},{"key":"2022010406275294500_b72","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s00467-007-0523-1","article-title":"Remission of membranoproliferative glomerulonephritis type I with the use of tacrolimus","volume":"22","author":"Haddad","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"2022010406275294500_b73","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s004670050557","article-title":"One-center experience with cyclosporine in refractory nephrotic syndrome in children","volume":"13","author":"Singh","year":"1999","journal-title":"Pediatr Nephrol"},{"key":"2022010406275294500_b74","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1159\/000064298","article-title":"Cyclosporin A treatment for membranoproliferative glomerulonephritis type II","volume":"91","author":"Kiyomasu","year":"2002","journal-title":"Nephron"},{"key":"2022010406275294500_b75","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1440-1797.2006.00763.x","article-title":"Mycophenolate mofetil treatment for therapy-resistant glomerulopathies","volume":"12","author":"Sahin","year":"2007","journal-title":"Nephrology (Carlton)"},{"key":"2022010406275294500_b76","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJM198405313102203","article-title":"Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy","volume":"310","author":"Donadio","year":"1984","journal-title":"N Engl J Med"},{"key":"2022010406275294500_b77","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/ndt\/9.6.619","article-title":"Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial. Collaborative Glomerulonephritis Therapy Study Group (CGTS)","volume":"9","author":"Zauner","year":"1994","journal-title":"Nephrol Dial Transplant"},{"key":"2022010406275294500_b78","first-page":"330","article-title":"Long-term corticosteroid and dipyridamole treatment of membranoproliferative glomerulonephritis type I in children","volume":"37","author":"Takeda","year":"1995","journal-title":"Nippon Jinzo Gakkai Shi"},{"key":"2022010406275294500_b79","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1159\/000183504","article-title":"Plasma exchange in the treatment of mesangiocapillary glomerulonephritis","volume":"40","author":"McGinley","year":"1985","journal-title":"Nephron"},{"key":"2022010406275294500_b80","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1159\/000168882","article-title":"Plasmapheresis maintained renal function in an allograft with recurrent membranoproliferative glomerulonephritis type I","volume":"15","author":"Muczynski","year":"1995","journal-title":"Am J Nephrol"},{"key":"2022010406275294500_b81","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0272-6386(00)70025-4","article-title":"Recurrent type I membranoproliferative glomerulonephritis in a renal allograft: successful treatment with plasmapheresis","volume":"35","author":"Saxena","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"2022010406275294500_b82","first-page":"418","article-title":"Regression of recurrent membranoproliferative glomerulonephritis type II in a transplanted kidney after plasmapheresis therapy","volume":"20","author":"Oberkircher","year":"1988","journal-title":"Transplant Proc"},{"key":"2022010406275294500_b83","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jca.10026","article-title":"Management of membranoproliferative glomerulonephritis type II with plasmapheresis","volume":"17","author":"Kurtz","year":"2002","journal-title":"J Clin Apher"},{"key":"2022010406275294500_b84","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1046\/j.1523-1755.1998.00765.x","article-title":"In situ complement activation in porcine membranoproliferative glomerulonephritis type II","volume":"53","author":"Jansen","year":"1998","journal-title":"Kidney Int"},{"key":"2022010406275294500_b85","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"key":"2022010406275294500_b86","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s004670050166","article-title":"Long-term therapy with enalapril in patients with nephrotic-range proteinuria","volume":"10","author":"Proesmans","year":"1996","journal-title":"Pediatr Nephrol"},{"key":"2022010406275294500_b87","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00467-005-2031-5","article-title":"Angiotensin blockade in children with chronic glomerulonephritis and heavy proteinuria","volume":"20","author":"Butani","year":"2005","journal-title":"Pediatr Nephrol"},{"key":"2022010406275294500_b88","first-page":"1245","article-title":"Effects of angiotensin converting enzyme inhibitor on renal function in patients of membranoproliferative glomerulonephritis with mild to moderate renal insufficiency","volume":"50","author":"Giri","year":"2002","journal-title":"J Assoc Physicians India"},{"key":"2022010406275294500_b89","first-page":"295","article-title":"A descriptive study of individuals with membranoproliferative glomerulonephritis","volume":"34","author":"Lu","year":"2007","journal-title":"J Nephrol Nurs"},{"key":"2022010406275294500_b90","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1097\/00007890-199706150-00016","article-title":"Recurrence of type I membranoproliferative glomerulonephritis after renal transplantation: analysis of the incidence, risk factors, and impact on graft survival","volume":"63","author":"Andresdottir","year":"1997","journal-title":"Transplantation"},{"key":"2022010406275294500_b91","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1399-0012.2005.00397.x","article-title":"Recurrent nephrotic syndrome after living-related renal transplantation resistant to plasma exchange: report of two cases","volume":"19","author":"Masutani","year":"2005","journal-title":"Clin Transplant"},{"key":"2022010406275294500_b92","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1681\/ASN.2005020175","article-title":"Recurrence of membranoproliferative glomerulonephritis type II in renal allografts: the North American Pediatric Renal Transplant Cooperative Study experience","volume":"16","author":"Braun","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2022010406275294500_b93","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/sj.ki.5000084","article-title":"Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk","volume":"69","author":"Little","year":"2006","journal-title":"Kidney Int"},{"key":"2022010406275294500_b94","first-page":"811","article-title":"Selective disappearance of C3NeF IgG autoantibody in the plasma of a patient with membranoproliferative glomerulonephritis following renal transplantation","volume":"9","author":"Fremeaux-Bacchi","year":"1994","journal-title":"Nephrol Dial Transplant"},{"key":"2022010406275294500_b95","volume-title":"Exploratory development of a therapeutic human plasma-derived factor H concentrate","author":"Mazurier","year":"2006"},{"key":"2022010406275294500_b96","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdg175","article-title":"An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab","volume":"14","author":"Boye","year":"2003","journal-title":"Ann Oncol"},{"key":"2022010406275294500_b97","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"key":"2022010406275294500_b98","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2004-12-4885","article-title":"Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report","volume":"106","author":"Galbusera","year":"2005","journal-title":"Blood"},{"key":"2022010406275294500_b99","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1182\/blood-2005-03-0848","article-title":"Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases","volume":"106","author":"Fakhouri","year":"2005","journal-title":"Blood"},{"key":"2022010406275294500_b100","volume-title":"Anti-FH lgG auto-antibodies and atypical HUS","author":"Dragon-Durey","year":"2006"},{"key":"2022010406275294500_b101","doi-asserted-by":"crossref","first-page":"9649","DOI":"10.1073\/pnas.0601094103","article-title":"Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice","volume":"103","author":"Pickering","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022010406275294500_b102","doi-asserted-by":"crossref","first-page":"II274","DOI":"10.1161\/01.CIR.0000138315.99788.eb","article-title":"Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass","volume":"110","author":"Lazar","year":"2004","journal-title":"Circulation"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2007.03558.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2007.03558.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/151\/2\/199\/42038534\/j.1365-2249.2007.03558.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/151\/2\/199\/42038534\/j.1365-2249.2007.03558.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T10:39:46Z","timestamp":1685702386000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/151\/2\/199\/6457598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,7]]},"references-count":102,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2007,12,7]]},"published-print":{"date-parts":[[2008,1,7]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2007.03558.x","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2008,2]]},"published":{"date-parts":[[2007,12,7]]}}}